Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 142   

Articles published

GSK 1,546.30 -6.70 (-0.43%)
price chart
GlaxoSmithKline plc 14.8% Potential Upside Indicated by Jefferies International
GlaxoSmithKline plc with EPIC/TICKER LON:GSK has had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' today by analysts at Jefferies International.
GlaxoSmithKline PLC (GSK) Downgraded by Zacks Investment Research  Sports Perspectives
GlaxoSmithKline plc (GSK) Given "Buy" Rating at Liberum Capital  The Cerbat Gem
GlaxoSmithKline could receive further Brexit boost, says broker
GlaxoSmithKline plc (LON:GSK) could receive a further Brexit boost if Prime Minister Theresa May takes a hard-line approach to the UK's disengagement from the European Union.
GlaxoSmithKline PLC (NYSE:GSK) Sale Analysis  The Newburgh Press
GlaxoSmithKline plc (NYSE:GSK) Beats Earnings by 50% percent  FactsReporter
Notable Stock Analysts Ratings: GlaxoSmithKline plc (NYSE:GSK)
GlaxoSmithKline plc (NYSE:GSK) will report its next earnings on Feb 1 - Feb 6 (Est.). The company reported the earnings of $0.85/Share in the last quarter where the estimated EPS by analysts was $0.74/share.
Why I'm bullish on GlaxoSmithKline plc for 2017
I believe GlaxoSmithKline (LSE: GSK) is one of the market's most undervalued and under-appreciated stocks. Over the past year, the company has gone from a business struggling to grow, to projected earnings per share growth of 30% this year and 10% for ...
GlaxoSmithKline PLC (GSK) to Post FY2016 Earnings of $2.47 Per Share ...
GlaxoSmithKline PLC logo GlaxoSmithKline PLC (NYSE:GSK) - Investment analysts at Jefferies Group increased their FY2016 EPS estimates for shares of GlaxoSmithKline PLC in a research note issued on Monday. Jefferies Group analyst J. Holford now ...
The FY2017 EPS Estimates for GlaxoSmithKline PLC Cut by Jefferies Group (GSK)  DailyQuint
Most Traded Stocks by Value at 17:00  Stock Market Wire
GlaxoSmithKline plc 10% Potential Upside Indicated by Jefferies International
GlaxoSmithKline plc using EPIC/TICKER code LON:GSK has had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' this morning by analysts at Jefferies International.
Simon Dingemans Buys 8 Shares of GlaxoSmithKline plc (GSK) Stock  Sports Perspectives
Shore Capital Reiterates Hold Rating for GlaxoSmithKline plc (GSK)  BBNS
Does this pharma's 56% sales growth make it a better buy than GlaxoSmithKline plc?
Reporting a 56% rise in sales for the first half of a financial year is a stunning performance by any investor's standards. Of course, the pharma stock in question was aided by weak sterling, which added 22% of those gains.
GlaxoSmithKline plc's (GSK) "Underperform" Rating Reaffirmed at BNP Paribas
GlaxoSmithKline plc logo BNP Paribas reiterated their underperform rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note issued to investors on Sunday morning.
Revenue Estimates Analysis: GlaxoSmithKline plc (NYSE:GSK)  News Oracle
GlaxoSmithKline plc (GSK) Rating Reiterated by BNP Paribas  The Cerbat Gem
GSK 'looks like a technical buy' for 2017
UK pharma giant GlaxoSmithKline plc (LON:GSK) is a 'technical buy' for the coming year after a volatile year for drugs stocks has seen the share price fall, says Zak Mir.
Zak Mir tips three big names to do well in 2017  MENAFN.COM
Does EKF Diagnostics Holding plc have more upside than GlaxoSmithKline plc ...
Point of care business EKF Diagnostics (LSE: EKF) has risen by over 5% today. This sharp hike in its share price is due to a positive update which shows that it has beaten expectations for the 2016 financial year.